Modulation  ||| S:0 E:11 ||| NNP
of  ||| S:11 E:14 ||| IN
Interleukin-8  ||| S:14 E:28 ||| NNP
and  ||| S:28 E:32 ||| CC
staphylococcal  ||| S:32 E:47 ||| JJ
flora  ||| S:47 E:53 ||| NNS
by  ||| S:53 E:56 ||| IN
Avène  ||| S:56 E:62 ||| NNP
hydrotherapy  ||| S:62 E:75 ||| NN
in  ||| S:75 E:78 ||| IN
patients  ||| S:78 E:87 ||| NNS
suffering  ||| S:87 E:97 ||| VBG
from  ||| S:97 E:102 ||| IN
chronic  ||| S:102 E:110 ||| JJ
inflammatory  ||| S:110 E:123 ||| NNS
dermatoses  ||| S:123 E:134 ||| VBP
A  ||| S:134 E:136 ||| DT
number  ||| S:136 E:143 ||| NN
of  ||| S:143 E:146 ||| IN
studies  ||| S:146 E:154 ||| NNS
argue  ||| S:154 E:160 ||| VBP
in  ||| S:160 E:163 ||| IN
favour  ||| S:163 E:170 ||| NN
of  ||| S:170 E:173 ||| IN
an  ||| S:173 E:176 ||| DT
important  ||| S:176 E:186 ||| JJ
role  ||| S:186 E:191 ||| NN
of  ||| S:191 E:194 ||| IN
microbial  ||| S:194 E:204 ||| JJ
colonization ||| S:204 E:216 ||| NN
,  ||| S:216 E:218 ||| ,
in  ||| S:218 E:221 ||| IN
particular  ||| S:221 E:232 ||| JJ
of  ||| S:232 E:235 ||| IN
Staphylococcus  ||| S:235 E:250 ||| NNP
aureus ||| S:250 E:256 ||| NN
,  ||| S:256 E:258 ||| ,
in  ||| S:258 E:261 ||| IN
triggering  ||| S:261 E:272 ||| VBG
atopic  ||| S:272 E:279 ||| JJ
dermatitis  ||| S:279 E:290 ||| NNS
( ||| S:290 E:291 ||| -LRB-
AD ||| S:291 E:293 ||| NNP
)  ||| S:293 E:295 ||| -RRB-
flare-up  ||| S:295 E:304 ||| JJ
and  ||| S:304 E:308 ||| CC
psoriasis ||| S:308 E:317 ||| NN
,  ||| S:317 E:319 ||| ,
in  ||| S:319 E:322 ||| IN
particular  ||| S:322 E:333 ||| JJ
through  ||| S:333 E:341 ||| IN
the  ||| S:341 E:345 ||| DT
superantigenic  ||| S:345 E:360 ||| JJ
properties  ||| S:360 E:371 ||| NNS
of  ||| S:371 E:374 ||| IN
toxins  ||| S:374 E:381 ||| VBG
generated  ||| S:381 E:391 ||| VBN
by  ||| S:391 E:394 ||| IN
S.  ||| S:394 E:397 ||| NNP
aureus ||| S:397 E:403 ||| NN
.  ||| S:403 E:405 ||| .
The  ||| S:405 E:409 ||| DT
aim  ||| S:409 E:413 ||| NN
of  ||| S:413 E:416 ||| IN
this  ||| S:416 E:421 ||| DT
study  ||| S:421 E:427 ||| NN
was  ||| S:427 E:431 ||| VBD
to  ||| S:431 E:434 ||| TO
assess  ||| S:434 E:441 ||| VB
the  ||| S:441 E:445 ||| DT
efficacy  ||| S:445 E:454 ||| NN
of  ||| S:454 E:457 ||| IN
a  ||| S:457 E:459 ||| DT
3-week  ||| S:459 E:466 ||| NNP
Avène  ||| S:466 E:472 ||| NNP
hydrotherapy  ||| S:472 E:485 ||| NN
on  ||| S:485 E:488 ||| IN
the  ||| S:488 E:492 ||| DT
skin  ||| S:492 E:497 ||| NN
surface  ||| S:497 E:505 ||| NN
of  ||| S:505 E:508 ||| IN
patients  ||| S:508 E:517 ||| NNS
suffering  ||| S:517 E:527 ||| VBG
from  ||| S:527 E:532 ||| IN
psoriasis  ||| S:532 E:542 ||| NN
or  ||| S:542 E:545 ||| CC
atopic  ||| S:545 E:552 ||| JJ
dermatitis ||| S:552 E:562 ||| NN
.  ||| S:562 E:564 ||| .
Skin  ||| S:564 E:569 ||| NN
samples  ||| S:569 E:577 ||| NNS
were  ||| S:577 E:582 ||| VBD
taken  ||| S:582 E:588 ||| VBN
from  ||| S:588 E:593 ||| IN
healthy  ||| S:593 E:601 ||| JJ
subjects  ||| S:601 E:610 ||| NNS
or  ||| S:610 E:613 ||| CC
atopic  ||| S:613 E:620 ||| NNS
( ||| S:620 E:621 ||| -LRB-
n  ||| S:621 E:623 ||| CD
=  ||| S:623 E:625 ||| SYM
18 ||| S:625 E:627 ||| CD
)  ||| S:627 E:629 ||| -RRB-
or  ||| S:629 E:632 ||| CC
psoriatic  ||| S:632 E:642 ||| JJ
patients  ||| S:642 E:651 ||| NNS
( ||| S:651 E:652 ||| -LRB-
n  ||| S:652 E:654 ||| CD
=  ||| S:654 E:656 ||| SYM
39 ||| S:656 E:658 ||| CD
)  ||| S:658 E:660 ||| -RRB-
undergoing  ||| S:660 E:671 ||| VBG
hydrotherapy  ||| S:671 E:684 ||| NN
at  ||| S:684 E:687 ||| IN
Avène  ||| S:687 E:693 ||| NNP
at  ||| S:693 E:696 ||| IN
the  ||| S:696 E:700 ||| DT
beginning  ||| S:700 E:710 ||| NN
( ||| S:710 E:711 ||| -LRB-
D0 ||| S:711 E:713 ||| NNP
)  ||| S:713 E:715 ||| -RRB-
and  ||| S:715 E:719 ||| CC
the  ||| S:719 E:723 ||| DT
end  ||| S:723 E:727 ||| NN
of  ||| S:727 E:730 ||| IN
treatment  ||| S:730 E:740 ||| NN
( ||| S:740 E:741 ||| -LRB-
D18 ||| S:741 E:744 ||| NNP
) ||| S:744 E:745 ||| -RRB-
.  ||| S:745 E:747 ||| .
The  ||| S:747 E:751 ||| DT
severity  ||| S:751 E:760 ||| NN
of  ||| S:760 E:763 ||| IN
the  ||| S:763 E:767 ||| DT
dermatosis  ||| S:767 E:778 ||| NN
was  ||| S:778 E:782 ||| VBD
evaluated  ||| S:782 E:792 ||| VBN
according  ||| S:792 E:802 ||| VBG
to  ||| S:802 E:805 ||| TO
SCORing  ||| S:805 E:813 ||| NNP
Atopic  ||| S:813 E:820 ||| NNP
Dermatitis  ||| S:820 E:831 ||| NNP
( ||| S:831 E:832 ||| -LRB-
SCORAD ||| S:832 E:838 ||| NNP
)  ||| S:838 E:840 ||| -RRB-
or  ||| S:840 E:843 ||| CC
Psoriasis  ||| S:843 E:853 ||| NNP
Area  ||| S:853 E:858 ||| NNP
Severity  ||| S:858 E:867 ||| NNP
Index  ||| S:867 E:873 ||| NNP
( ||| S:873 E:874 ||| -LRB-
PASI ||| S:874 E:878 ||| NNP
)  ||| S:878 E:880 ||| -RRB-
scores  ||| S:880 E:887 ||| NNS
at  ||| S:887 E:890 ||| IN
D0  ||| S:890 E:893 ||| NNP
and  ||| S:893 E:897 ||| CC
D18 ||| S:897 E:900 ||| NNP
.  ||| S:900 E:902 ||| .
Marker  ||| S:902 E:909 ||| NNP
of  ||| S:909 E:912 ||| IN
inflammation  ||| S:912 E:925 ||| CD
interleukin  ||| S:925 E:937 ||| CD
8  ||| S:937 E:939 ||| CD
( ||| S:939 E:940 ||| -LRB-
IL-8 ||| S:940 E:944 ||| NNP
) ||| S:944 E:945 ||| -RRB-
,  ||| S:945 E:947 ||| ,
S.  ||| S:947 E:950 ||| NNP
aureus  ||| S:950 E:957 ||| FW
colonization  ||| S:957 E:970 ||| FW
( ||| S:970 E:971 ||| -LRB-
protein  ||| S:971 E:979 ||| NN
A ||| S:979 E:980 ||| NNP
)  ||| S:980 E:982 ||| -RRB-
and  ||| S:982 E:986 ||| CC
enterotoxins  ||| S:986 E:999 ||| NNS
were  ||| S:999 E:1004 ||| VBD
assessed  ||| S:1004 E:1013 ||| VBN
in  ||| S:1013 E:1016 ||| IN
skin  ||| S:1016 E:1021 ||| NN
samples  ||| S:1021 E:1029 ||| NNS
using  ||| S:1029 E:1035 ||| VBG
RT-PCR ||| S:1035 E:1041 ||| JJ
.  ||| S:1041 E:1043 ||| .
At  ||| S:1043 E:1046 ||| IN
D0 ||| S:1046 E:1048 ||| NNP
,  ||| S:1048 E:1050 ||| ,
significant  ||| S:1050 E:1062 ||| JJ
differences  ||| S:1062 E:1074 ||| NNS
were  ||| S:1074 E:1079 ||| VBD
observed  ||| S:1079 E:1088 ||| VBN
between  ||| S:1088 E:1096 ||| IN
healthy  ||| S:1096 E:1104 ||| JJ
subjects  ||| S:1104 E:1113 ||| NNS
and  ||| S:1113 E:1117 ||| CC
atopic  ||| S:1117 E:1124 ||| NNS
or  ||| S:1124 E:1127 ||| CC
psoriatic  ||| S:1127 E:1137 ||| JJ
patients  ||| S:1137 E:1146 ||| NNS
in  ||| S:1146 E:1149 ||| IN
all  ||| S:1149 E:1153 ||| PDT
the  ||| S:1153 E:1157 ||| DT
parameters  ||| S:1157 E:1168 ||| JJ
evaluated  ||| S:1168 E:1178 ||| NNS
( ||| S:1178 E:1179 ||| -LRB-
IL-8 ||| S:1179 E:1183 ||| NNP
,  ||| S:1183 E:1185 ||| ,
protein  ||| S:1185 E:1193 ||| NN
A ||| S:1193 E:1194 ||| NNP
) ||| S:1194 E:1195 ||| -RRB-
.  ||| S:1195 E:1197 ||| .
At  ||| S:1197 E:1200 ||| IN
the  ||| S:1200 E:1204 ||| DT
end  ||| S:1204 E:1208 ||| NN
of  ||| S:1208 E:1211 ||| IN
the  ||| S:1211 E:1215 ||| DT
hydrotherapy ||| S:1215 E:1227 ||| NN
,  ||| S:1227 E:1229 ||| ,
a  ||| S:1229 E:1231 ||| DT
significant  ||| S:1231 E:1243 ||| JJ
decrease  ||| S:1243 E:1252 ||| NN
in  ||| S:1252 E:1255 ||| IN
SCORAD  ||| S:1255 E:1262 ||| NNP
was  ||| S:1262 E:1266 ||| VBD
associated  ||| S:1266 E:1277 ||| VBN
with  ||| S:1277 E:1282 ||| IN
a  ||| S:1282 E:1284 ||| DT
significant  ||| S:1284 E:1296 ||| JJ
reduction  ||| S:1296 E:1306 ||| NN
of  ||| S:1306 E:1309 ||| IN
IL-8 ||| S:1309 E:1313 ||| NNP
,  ||| S:1313 E:1315 ||| ,
S.  ||| S:1315 E:1318 ||| NNP
aureus  ||| S:1318 E:1325 ||| NN
colonization  ||| S:1325 E:1338 ||| NNS
and  ||| S:1338 E:1342 ||| CC
enterotoxin  ||| S:1342 E:1354 ||| JJ
D  ||| S:1354 E:1356 ||| NNP
in  ||| S:1356 E:1359 ||| IN
patients  ||| S:1359 E:1368 ||| NNS
with  ||| S:1368 E:1373 ||| IN
atopic  ||| S:1373 E:1380 ||| JJ
dermatitis ||| S:1380 E:1390 ||| NN
.  ||| S:1390 E:1392 ||| .
Similarly ||| S:1392 E:1401 ||| RB
,  ||| S:1401 E:1403 ||| ,
a  ||| S:1403 E:1405 ||| DT
significant  ||| S:1405 E:1417 ||| JJ
decrease  ||| S:1417 E:1426 ||| NN
in  ||| S:1426 E:1429 ||| IN
PASI  ||| S:1429 E:1434 ||| NNP
was  ||| S:1434 E:1438 ||| VBD
associated  ||| S:1438 E:1449 ||| VBN
with  ||| S:1449 E:1454 ||| IN
a  ||| S:1454 E:1456 ||| DT
significant  ||| S:1456 E:1468 ||| JJ
reduction  ||| S:1468 E:1478 ||| NN
of  ||| S:1478 E:1481 ||| IN
IL-8 ||| S:1481 E:1485 ||| NNP
,  ||| S:1485 E:1487 ||| ,
S.  ||| S:1487 E:1490 ||| NNP
aureus  ||| S:1490 E:1497 ||| NN
colonization  ||| S:1497 E:1510 ||| NNS
and  ||| S:1510 E:1514 ||| CC
enterotoxin  ||| S:1514 E:1526 ||| JJ
N  ||| S:1526 E:1528 ||| NNP
in  ||| S:1528 E:1531 ||| IN
patients  ||| S:1531 E:1540 ||| NNS
with  ||| S:1540 E:1545 ||| IN
psoriasis ||| S:1545 E:1554 ||| NN
.  ||| S:1554 E:1556 ||| .
This  ||| S:1556 E:1561 ||| DT
study  ||| S:1561 E:1567 ||| NN
demonstrates  ||| S:1567 E:1580 ||| VBZ
the  ||| S:1580 E:1584 ||| DT
positive  ||| S:1584 E:1593 ||| JJ
effects  ||| S:1593 E:1601 ||| NNS
of  ||| S:1601 E:1604 ||| IN
Avène  ||| S:1604 E:1610 ||| NNP
hydrotherapy  ||| S:1610 E:1623 ||| NN
on  ||| S:1623 E:1626 ||| IN
the  ||| S:1626 E:1630 ||| DT
skin  ||| S:1630 E:1635 ||| NN
of  ||| S:1635 E:1638 ||| IN
patients  ||| S:1638 E:1647 ||| NNS
suffering  ||| S:1647 E:1657 ||| VBG
from  ||| S:1657 E:1662 ||| IN
chronic  ||| S:1662 E:1670 ||| JJ
dermatosis ||| S:1670 E:1680 ||| NN
,  ||| S:1680 E:1682 ||| ,
with  ||| S:1682 E:1687 ||| IN
decreased  ||| S:1687 E:1697 ||| JJ
inflammation  ||| S:1697 E:1710 ||| NN
and  ||| S:1710 E:1714 ||| CC
reduced  ||| S:1714 E:1722 ||| JJ
colonization  ||| S:1722 E:1735 ||| NN
by  ||| S:1735 E:1738 ||| IN
S.  ||| S:1738 E:1741 ||| NNP
aureus ||| S:1741 E:1747 ||| NN
.  ||| S:1747 E:1749 ||| .
